INSURANCE/HEALTH: Requires drug manufacturers to limit pricing of GLP-1 medications for health insurance plans (OR INCREASE GF EX See Note)

HB 920 requires drug manufacturers to limit out-of-pocket costs for GLP-1 medications (used for diabetes and obesity treatment) under health insurance plans in Louisiana. It caps patient costs at $200 per 30-day prescription, regardless of the specific medication or medical condition. The bill also mandates that Louisiana Medicaid cover GLP-1 medications without condition-based restrictions when prescribed. These provisions apply to all health coverage plans, including Medicaid, and may require federal waiver approvals for implementation. The bill is currently in the prefiling stage with no votes recorded.